ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements with these filters
Beryl Drugs Ltd has notified a board meeting on 14 November 2026 to consider unaudited results for the quarter ended 30 September 2026 and the limited review report. The trading window stays closed until 48 hours after the meeting.
Beryl Drugs Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Beryl Drugs Limited has submitted its quarterly compliance certificates regarding Regulation 74(5) and a non-applicability confirmation for Regulation 57(5) for the quarter ended September 30, 2026.
Beryl Drugs Limited held its 33rd Annual General Meeting on September 29, 2026. Shareholders approved audited financial statements, director reappointment, and increased related-party transaction limits.
Beryl Drugs Ltd has submitted its 33rd Annual Report for the financial year 2025-26, scheduled for its upcoming Annual General Meeting.
Beryl Drugs Ltd has announced the closure of its register of members from September 23 to September 29, 2026, for its 33rd Annual General Meeting.
Beryl Drugs Limited approved items for its 33rd Annual General Meeting and a proposal to increase material related party transaction limits.
Beryl Drugs Ltd has scheduled a Board Meeting for September 2, 2026, to approve the Board report and matters related to its 33rd Annual General Meeting.
Sudhir Sethi, a promoter of Beryl Drugs Limited, acquired 3,000 equity shares via market transactions. This acquisition increases the promoter's total stake from 10.08% to 10.14%.
Beryl Drugs Ltd reported revenue from operations of ₹7.3 Cr (+52.1% YoY) and net profit of ₹0.2 Cr for Q1 FY27.
Beryl Drugs Ltd's board meeting on August 11, 2026, approved the unaudited financial results for the quarter ended June 30, 2026.
Beryl Drugs Ltd's Board of Directors will meet on August 11, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.
Beryl Drugs Ltd reported the temporary unavailability of its corporate website due to technical issues. The company stated there is no impact on business operations.
Promoter Sudhir Sethi acquired 6,950 shares of Beryl Drugs Ltd via market transactions. This increases the promoter's stake by 0.14% to a total of 10.055%.
Beryl Drugs Ltd will shift its registered office within Indore to Neer Nagar effective 1 July 2026. The change is for administrative convenience and leaves the CIN unchanged.
Beryl Drugs Ltd approved relocation of its registered office within Indore. The move does not affect operations but updates the company's registered address.
Beryl Drugs scheduled a board meeting for June 16, 2026. The board will consider shifting the company's registered office within the local limits of Indore.
Promoter Mr. Sudhir Sethi acquired 1,992 equity shares of Beryl Drugs Limited through open market transactions. The purchase increases his total stake to 9.75%.
Beryl Drugs Ltd reported revenue from operations of ₹5.5 Cr (+5.8% YoY) and net profit of ₹0.6 Cr (+200.0% YoY) for Q4 FY26.
Beryl Drugs reported annual revenue of ₹19.31 Crore for FY2026. The results include an unmodified audit opinion despite temporary manufacturing suspensions in the BFS section.
Beryl Drugs Ltd approved its audited financial statements and related party transactions during its board meeting. Results for the fiscal year ended March 2026 were confirmed.
Beryl Drugs Ltd scheduled a board meeting on May 28, 2026, to approve audited financial results. The meeting will also consider related party transactions.
Beryl Drugs Limited concluded its Extra-Ordinary General Meeting on May 11, 2026. Shareholders approved director appointments and material related party transactions through remote e-voting and polling.
Beryl Drugs Limited shareholders approved all resolutions at the May 11 EGM with 100% favor. Appointments and related party transactions were passed unanimously by the company.
Beryl Drugs Limited shareholders approved new director appointments and material related party transactions during the EGM. The meeting concluded successfully with all requisite majorities.
Beryl Drugs Ltd submitted a certificate claiming exemption from Corporate Governance provisions under Regulation 15(2) of SEBI LODR for the year ended March 31, 2026. The company qualifies for the exemption as its paid-up capital (₹5.07 Crore) and net worth (₹9.50 Crore) remain below the prescribed regulatory thresholds.
Beryl Drugs Ltd (BSE: 524606) has submitted its initial disclosure confirming it is not identified as a Large Corporate as of March 31, 2026. The company reported outstanding borrowings of ₹2.39 Crore, falling below the SEBI threshold for large corporate classification.
Beryl Drugs Ltd has submitted its quarterly compliance reports for the period ended March 31, 2026. The filing includes certificates regarding dematerialisation of securities and maintenance of share transfer facilities. These are routine regulatory submissions ensuring administrative and operational transparency for shareholders.
Beryl Drugs Ltd submitted compliance certificates for the quarter and year ended March 31, 2026. The filings confirm maintenance of share transfer facilities by Adroit Corporate Services and compliance with SEBI depository and non-applicability regulations.